- Ikena Oncology Inc at Jefferies Healthcare Conference TranscriptJun 08, 2023
- Ikena Oncology Inc at Stifel Targeted Oncology Days (Virtual) TranscriptApr 25, 2023
- Ikena Oncology Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 14, 2022
- Ikena Oncology Inc at Stifel Healthcare Conference (Virtual) TranscriptNov 15, 2021
- Ikena Oncology Inc at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 11, 2021
Ikena Oncology Inc at Stifel Targeted Oncology Days (Virtual) Transcript
All right. Thanks, everyone. I'm Stephen Willey, one of the senior analysts here at Stifel, and glad to have with us presenting from Ikena Oncology, CEO, Mark Manfredi. He's going to be giving us a presentation. If there's some time left for Q&A, we'll get into it. I think there's a chat function as well that can be used to populate any investor questions that you may have. So Mark, I'm going to turn it over to you, and really appreciate the participation today. Thank you.
Thanks, Stephen, and thanks for the invitation to talk about the company. And so I'm going to start just a little bit of an overview of us. So Ikena Oncology. We're focused on targeted oncology, clinical assets in the pipeline. And we're really on two pathways. One is the Hippo pathway, which I'll spend most of the time today, which is a first-in-class opportunity to target a transcription factor called TEAD. And in the second is a well-known pathway called the RAS pathway
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)